Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Shilpa Medicare Limited ( (IN:SHILPAMED) ).
Shilpa Medicare Limited has disclosed that the Delhi High Court has issued an ex-parte ad-interim injunction restraining the company, its material subsidiary Shilpa Pharma Lifesciences and wholly owned subsidiary FTF Pharma from manufacturing, stockpiling, importing, exporting or supplying pharmaceutical products containing the compound Ruxolitinib and/or its salts in any form that may infringe a specified Indian patent. A court-appointed Local Commissioner inspected the company’s premises and collected records, with Shilpa Medicare stating it fully cooperated and that the Ruxolitinib-related product was used solely for research purposes, resulting in no financial impact or disruption to its ongoing business operations. The company has acknowledged the order, is complying with its directions and is evaluating legal options, including filing responses or appeals, as it manages the potential intellectual property dispute while maintaining normal operations.
More about Shilpa Medicare Limited
Shilpa Medicare Limited is an India-based pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients (APIs), formulations and specialty drug products, with operations supported by material and wholly owned subsidiaries such as Shilpa Pharma Lifesciences and FTF Pharma. The company focuses on complex and research-driven pharmaceutical products, supplying to both domestic and international markets.
Average Trading Volume: 28,711
Technical Sentiment Signal: Hold
Current Market Cap: 62.56B INR
For a thorough assessment of SHILPAMED stock, go to TipRanks’ Stock Analysis page.